CONTEXT: In the era of serum prostate-specific antigen (PSA) screening, the incidence of prostate cancer has increased dramatically. Simultaneously however, stage migration has occurred, and treatment outcomes have improved. Inner-city men have lower screening rates and, thus, may be diagnosed with more advanced disease that it less likely to be successfully treated. OBJECTIVE: To assess the detection rate of prostate cancer and tumor stage at presentation in inner-city men. DESIGN, SETTING, AND PATIENTS: A retrospective cohort of 368 men underwent transrectal ultrasound needle-guided biopsy at an inner-city hospital from January 2003 to May 2005. Clinical and pathologic data were collected and analyzed. MAIN OUTCOME MEASURES: Clinic and hospital records were reviewed for several key outcomes, including prostate cancer incidence, tumor stage and tumor grade. RESULTS: The median age of the cohort was 67 +/- 9.1 years (range, 23-93 years). Prostate cancer was diagnosed in 44% of subjects (161/368). The median PSA level at the time of diagnosis was significantly higher in African-American men than in Caucasian men (9.82 vs. 5.97 ng/mL, P=0.008). Abnormally high serum PSA levels (>20 ng/mL) were present in disproportionately more African-American men than Caucasian men with prostate cancer (32.9% vs. 19.7% P=0.011). African-American men in this inner-city cohort also had a higher incidence of advanced disease or distant metastasis (T3/T4, N1, or M1) than did Caucasians (16.1% vs. 3.8%; P=0.045). CONCLUSIONS: Compared with inner-city Caucasian men, disproportionately more inner-city, African-American men present with advanced prostate cancer. This observation warrants prostate cancer education and consideration of early detection programs in underserved inner-city communities.
CONTEXT: In the era of serum prostate-specific antigen (PSA) screening, the incidence of prostate cancer has increased dramatically. Simultaneously however, stage migration has occurred, and treatment outcomes have improved. Inner-city men have lower screening rates and, thus, may be diagnosed with more advanced disease that it less likely to be successfully treated. OBJECTIVE: To assess the detection rate of prostate cancer and tumor stage at presentation in inner-city men. DESIGN, SETTING, AND PATIENTS: A retrospective cohort of 368 men underwent transrectal ultrasound needle-guided biopsy at an inner-city hospital from January 2003 to May 2005. Clinical and pathologic data were collected and analyzed. MAIN OUTCOME MEASURES: Clinic and hospital records were reviewed for several key outcomes, including prostate cancer incidence, tumor stage and tumor grade. RESULTS: The median age of the cohort was 67 +/- 9.1 years (range, 23-93 years). Prostate cancer was diagnosed in 44% of subjects (161/368). The median PSA level at the time of diagnosis was significantly higher in African-American men than in Caucasian men (9.82 vs. 5.97 ng/mL, P=0.008). Abnormally high serum PSA levels (>20 ng/mL) were present in disproportionately more African-American men than Caucasian men with prostate cancer (32.9% vs. 19.7% P=0.011). African-American men in this inner-city cohort also had a higher incidence of advanced disease or distant metastasis (T3/T4, N1, or M1) than did Caucasians (16.1% vs. 3.8%; P=0.045). CONCLUSIONS: Compared with inner-city Caucasian men, disproportionately more inner-city, African-American men present with advanced prostate cancer. This observation warrants prostate cancer education and consideration of early detection programs in underserved inner-city communities.
Authors: Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson Journal: N Engl J Med Date: 2005-05-12 Impact factor: 91.245
Authors: Peter A S Johnstone; Christopher J Kane; Leon Sun; Hongyu Wu; Judd W Moul; David G McLeod; Douglas D Martin; Leo Kusuda; Raymond Lance; Robert Douglas; Timothy Donahue; Michael G Beat; John Foley; Dalton Baldwin; Douglas Soderdahl; Jason Do; Christopher L Amling Journal: Radiology Date: 2002-11 Impact factor: 11.105
Authors: R M Hoffman; F D Gilliland; J W Eley; L C Harlan; R A Stephenson; J L Stanford; P C Albertson; A S Hamilton; W C Hunt; A L Potosky Journal: J Natl Cancer Inst Date: 2001-03-07 Impact factor: 13.506
Authors: A B Jani; F Vaida; G Hanks; S Asbell; O Sartor; J W Moul; M Roach; D Brachman; U Kalokhe; R Muller-Runkel; P Ray; L Ignacio; A Awan; R R Weichselbaum; S Vijayakumar Journal: Int J Cancer Date: 2001-12-20 Impact factor: 7.396
Authors: G Bartsch; W Horninger; H Klocker; A Reissigl; W Oberaigner; D Schönitzer; G Severi; C Robertson; P Boyle Journal: Urology Date: 2001-09 Impact factor: 2.649
Authors: Andreas P Berger; Christian Gozzi; Hannes Steiner; Ferdinand Frauscher; John Varkarakis; Hermann Rogatsch; Georg Bartsch; Wolfgang Horninger Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Deborah E Blocker; LaHoma Smith Romocki; Kamilah B Thomas; Belinda L Jones; Ethel Jean Jackson; LaVerne Reid; Marci K Campbell Journal: J Natl Med Assoc Date: 2006-08 Impact factor: 1.798
Authors: Laura C Bouchard; Betina Yanez; Jason R Dahn; Sarah C Flury; Kent T Perry; David C Mohr; Frank J Penedo Journal: Transl Behav Med Date: 2019-07-16 Impact factor: 3.046
Authors: John Pendleton; Christopher Hopkins; Satoshi Anai; Kogenta Nakamura; Myron Chang; Anthony Grissett; Charles J Rosser Journal: J Cancer Educ Date: 2008 Impact factor: 2.037
Authors: Christian J Nelson; Tatiana D Starr; Richard J Macchia; Llewellyn Hyacinthe; Steven Friedman; Andrew J Roth Journal: Support Care Cancer Date: 2016-02-04 Impact factor: 3.603